|MDACC Study No:||2011-0287 (clinicaltrials.gov NCT No: NCT01440179)|
|Title:||Phase II two stage dose finding run-in study of SAR3419, an anti-CD19 antibody-maytansine conjugate, administered as a single agent by intravenous infusion in patients with relapsed or Refractory Acute Lymphoblastic Leukemia (ALL) |
|Principal Investigator:||Hagop Kantarjian|
|Study Description:||The goal of this clinical research study is to learn if SAR3419 can help to |
control ALL. The safety of the study drug will also be studied.
SAR3419 is a substance that can locate and bind to CD19, a molecule that is
found on most ALL cells. This may cause the cancer cells to die.